Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CureVac (CVAC) Short-term Investments (2019 - 2025)

Historic Short-term Investments for CureVac (CVAC) over the last 7 years, with Q3 2025 value amounting to $3.7 million.

  • CureVac's Short-term Investments fell 1801.64% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year decrease of 1801.64%. This contributed to the annual value of $3.9 million for FY2024, which is 3518.51% up from last year.
  • Latest data reveals that CureVac reported Short-term Investments of $3.7 million as of Q3 2025, which was down 1801.64% from $3.5 million recorded in Q2 2025.
  • In the past 5 years, CureVac's Short-term Investments registered a high of $48.3 million during Q2 2021, and its lowest value of $2.6 million during Q3 2022.
  • Moreover, its 5-year median value for Short-term Investments was $4.0 million (2024), whereas its average is $6.8 million.
  • In the last 5 years, CureVac's Short-term Investments soared by 68953790.83% in 2021 and then plummeted by 9202.91% in 2022.
  • Quarter analysis of 5 years shows CureVac's Short-term Investments stood at $5.3 million in 2021, then fell by 13.9% to $4.6 million in 2022, then plummeted by 37.46% to $2.9 million in 2023, then surged by 35.19% to $3.9 million in 2024, then dropped by 5.67% to $3.7 million in 2025.
  • Its Short-term Investments was $3.7 million in Q3 2025, compared to $3.5 million in Q2 2025 and $4.0 million in Q1 2025.